I. Dyakov

发表

[Vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration].

I. Dyakov, S. Zyryanov, 2017, Vestnik oftalmologii.

Immunogenicity of the drug "Live intranasal vaccine for the prevention of pertussis" (GamLPV) with a single use in healthy volunteers

I. Dyakov, A. Medkova, A. A. Lidzhiyeva, 2022, Journal of microbiology, epidemiology and immunobiology.

Comparative immunogenicity and structural analysis of epitopes of different bacterial L-asparaginases

M. Kazanov, M. Pokrovskaya, V. Pokrovsky, 2016, BMC Cancer.

Pharmacoeconomic analysis of taliglucerase alfa used in the Russian Federation for Gaucher’s disease

I. Dyakov, S. Zyryanov, 2021 .

Cost analysis of dual antiplatelet therapy with prasugrel and ticagrelor in patients with acute coronary syndrome after percutaneous coronary intervention

I. Dyakov, E. Ushkalova, 2020 .

harmacoeconomic feasibility of using the drug upadacitinib in patients with rheumatoid arthritis in the healthcare system of the Russian Federation

I. Dyakov, S. Zyryanov, A. Lila, 2020 .

Pharmacoeconomic aspects of oral vinorelbine application: a budget impact analysis considering the new registered price

I. Dyakov, S. Zyryanov, D. Ivanov, 2021, FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology.

[Clinical and economic efficiency of treatment with cariprazine in schizophrenia].

I. Dyakov, S. Zyryanov, 2019, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

Comparative clinical and economic assessment of polatuzumab vedotin therapy in combination with bendamustine and rituximab for adult transplantation-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma

I. Dyakov, K. K. Bushkova, 2022, Oncohematology.

[Evaluation of the pharmacoeconomic efficacy of prestance in the treatment of hypertensive patients on the basis of the results of the POTENTIAL program].

M. Glezer, I. Dyakov, 2016, Terapevticheskii arkhiv.

Plasma methionine depletion and pharmacokinetic properties in mice of methionine γ-lyase from Citrobacter freundii, Clostridium tetani and Clostridium sporogenes.

V. Pokrovsky, M. V. Komarova, T. Demidkina, 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[The pharmacoeconomic efficacy of lurasidone in the treatment of schizophrenia].

I. Dyakov, S. Zyryanov, E. Mosolova, 2020, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

Effect of microenvironment on functional activity of murine B-lymphocytes

I. Dyakov, I. Chernyshova, M. Gavrilova, 2008, Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology.

Comparative immunogenicity and structural analysis of epitopes of different bacterial L-asparaginases

M. Kazanov, M. Pokrovskaya, V. Pokrovsky, 2016, BMC Cancer.

[Pharmacoeconomics analysis of using a fixed combination of budesonide/formoterol in patients with asthma in the health care system of the Russian Federation].

Z. Aisanov, I. Dyakov, S. Zyryanov, 2022, Terapevticheskii arkhiv.

Development of a Method and a Scheme for the Use of a Live Recombinant Vaccine "GamLPV". Safety and Tolerability of Double Intranasal Vaccination of Healthy Adult Volunteers

I. Dyakov, S. Smetanina, E. Smolyarchuk, 2022, Drug development & registration.

The economic side of an oral sugar lowering therapy intensification by glucagon-like peptidt-1 receptor agonists

I. Dyakov, S. Zyryanov, 2022, Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice.

Live attenuated COVID-19 vaccines: approaches to development and prospects for clinical use

E. Faizuloev, I. Dyakov, A. Gracheva, 2023, Journal of microbiology, epidemiology and immunobiology.

Pharmacoeconomic comparison of insulin glargine and insulin detemir in diabetes mellitus type 2

I. Dyakov, S. Zyryanov, 2020 .

Pharmacoeconomic feasibility of using the drug Hemangiol (propranolol, oral solution) in the treatment of proliferating infantile hemangioma requiring systemic therapy

I. Dyakov, S. R. Varfolomeеva, 2021, FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology.

Pharmacoeconomical analysis of the use of upadacitinib, baricitinib and dupilumab for systemic therapy of patients with moderate and severe atopic dermatitis

I. Dyakov, S. Zyryanov, N. Ilina, 2023, Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice.

FN3 protein fragment containing two type III fibronectin domains from B. longum GT15 binds to human tumor necrosis factor alpha in vitro

V. Danilenko, M. Dyachkova, I. Dyakov, 2020, Anaerobe.

Pharmacoeconomic analysis of the use of a fixed combination of tiotropium bromide and olodaterol as maintenance therapy in patients with chronic obstructive pulmonary disease in the Russian Federation

I. Dyakov, S. Zyryanov, 2022, FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology.

Pharmacoeconomic characteristics of agonists of receptors for glucagon-like peptide-1 and medicines on their base

I. Dyakov, S. Zyryanov, 2021, Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice.

Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base

I. Dyakov, S. Zyryanov, 2021, Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice.

A Clinical Study of the Safety and Tolerability of Live Nasal Vaccines for the Prevention of Pertussis

I. Dyakov, S. Smetanina, A. Medkova, 2021, Drug development & registration.

[Vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration].

I. Dyakov, S. Zyryanov, 2017, Vestnik oftalmologii.